Background: Child-friendly, low-cost, solid, oral fixed-dose combinations (FDCs) of efavirenz with lamivudine and abacavir are urgently needed to improve clinical management and drug adherence for children.
Introduction
Despite significant progress over the past two decades in preventing mother to child transmission of HIV, paediatric HIV remains a major public health problem. Over 90% of the global paediatric HIV population is in sub-Saharan Africa. 1 ART has considerably reduced mortality and transformed the prognosis of HIV infection from a once deadly disease into a manageable chronic illness.
The 2015 WHO ARV Consolidated guidelines confirm the preferred first-line antiretroviral regimen for children weighing 10 -35 kg ( 3 -10 years old) to comprise a combination of abacavir, lamivudine and efavirenz. Fixed-dose combinations (FDCs) allow simplified dosing, but, to date, no paediatric FDC tablet of efavirenz/lamivudine/abacavir is available. The challenges of developing a multi-drug combination tablet in children include different routes of metabolism and elimination for the different drugs. For the youngest, ,2 years old, it also includes different rates of maturation for the mechanisms involved in the absorption, distribution, metabolism and excretion of the different drugs. Moreover, efavirenz pharmacokinetics is influenced by host genetic polymorphisms, such as the cytochrome P450 (CYP) 2B6-516G .T gene polymorphism, which is strongly associated with higher plasma concentrations. 2, 3 To develop a paediatric FDC of efavirenz/lamivudine/abacavir, it is necessary to determine the optimal doses of these drugs within the FDC that will provide appropriate dosing across all weight bands through simple dose increments. Using the current WHO weight band-based dosing recommendations for each drug does not always lead to a single drug ratio across weight bands.
A dose-modelling tool (http://www.who.int/hiv/paediatric/ generictool/en/index.html) was used to predict the dose delivered for each component drug versus the recommended dosing schedule. This tool calculates doses on a mg/kg basis using the dose approved for a given antiretroviral and applies a linear assumption that was considered to be appropriate for children 3 years and older as targeted by this project. In some cases the dose identified for a particular weight band may be somewhat above or below the dose recommended by the manufacturer. This is inevitable given the limitations imposed by an FDC, but the tool ensures that in no case would a child receive .25% above the maximum or .5% below the minimum recommended dose. A simplified dosing is then extrapolated for WHO weight bands. Thereafter, three FDC options have been considered for efavirenz/lamivudine/abacavir, namely (I) 150/75/150, (II) 120/60/120 and (III) 200/100/200 mg. A pharmacokinetic meta-analysis of paediatric data for efavirenz was performed to develop a population pharmacokinetic model. For abacavir and lamivudine, previously published models were used. Using these models, the three proposed paediatric FDC strength options of efavirenz/lamivudine/abacavir were investigated in order to determine the proportion of children whose drug exposure would fall within efficacy and safety targets for each of the WHO weight bands. The optimal efavirenz targets were based on mid-dose interval efavirenz concentrations of between 1 and 4 mg/L. 4 -6 There is currently no consensus regarding the pharmacokinetic targets for NRTI plasma concentrations, including lamivudine and abacavir. Thereafter, we tried to mimic the distribution of the AUCs observed in adults for both of these drugs. Regarding the weight band cut-off, this is predefined by WHO weight bands, which are globally recognized and widely used in sub-Saharan Africa, and hence alternative weight bands would have not been suitable for a public health approach.
Methods

Source of the data Efavirenz
The data to generate the efavirenz pharmacokinetic model were pooled from seven published studies: (i) IMPAACT P1021; 7 (ii) ARROW study; 8 (iii) a paediatric cohort study in Thailand; 9 (iv and v) two pharmacokinetic studies from South Africa; 10, 11 (vi) the ANRS12103 (Burkiname) study in Burkina Faso; 12 and (vii) the CHAPAS-3 study.
13
Lamivudine and abacavir
These datasets and their analyses have been previously described in detail. 14 -17 There were 187/1231 and 920/3820 subjects/observations available for the abacavir and lamivudine analyses, respectively. Table S1 (available as Supplementary data at JAC Online) summarizes patient characteristics for abacavir and lamivudine.
Ethics
Ethics approvals were obtained for each of the included studies as previously described.
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Analytical methods
The analytical methods have been previously described in the original published articles for each analysis (see above). The lower limit of quantification (LOQ) for efavirenz was 0.05 mg/L.
Population pharmacokinetic model development
Drug concentration data were analysed using the non-linear mixed-effect modelling program NONMEM (version 6.2) 18 driven by Wings for NONMEM (http://wfn.sourceforge.net). The parameter estimation was based upon the first-order conditional estimation (FOCE) method with the interaction option (INTER). Different statistical models were investigated (i.e. exponential, proportional and/or additive) to describe residual variability. The between-subject variability (BSV or v) and between-occasion variability (BOV or C) was described with an exponential model. An occasion was defined as one drug intake on 1 day. The objective function value (OFV, statistical criterion to be minimized) was used to test different hypotheses regarding the final model, i.e. (i) covariate effect(s) on pharmacokinetic parameter(s) and (ii) structure of the variance -covariance matrix for the BSV parameters. The main covariates of interest in the population were age, body weight and CYP2B6-516G .T polymorphism (for efavirenz). A mixture model was used for imputation of the subjects for which no genotype result was available. Clearance and volume parameter estimates were standardized to a reference body weight using an allometric model:
PWR where P STD is the standard value of parameter for a patient with the standard body weight value (70 kg) and P i and BW i are the parameter and body weight value of the ith individual. The PWR exponents may be estimated from the data. However, from allometric scaling theory and practice these are typically fixed to 0.75 for clearance (CL) parameters and 1 for volumes of distribution (V). 19 For evaluation of the model goodness-of-fit, the following graphs were drawn: observed and model predicted concentrations versus time, observed concentrations versus population predictions, weighted residuals versus time and weighted residuals versus predictions. Similar graphs using individual predictive estimation were examined. Diagnostic graphics were obtained with the R statistical package using Rfn (http:// wfn.sourceforge.net). 20 The accuracy and robustness of the final population model were assessed using a bootstrap method. From the original dataset of n individuals, B bootstrap sets (B ¼ 1000) of n individuals are drawn with replacement (resampling). For each bootstrap sample, the population pharmacokinetic parameters are estimated, and then parameter statistics obtained from the whole bootstrap set. To evaluate the model, the parameters estimated from the bootstrap must be close to estimates obtained from the original population set. The entire procedure was performed in an automated fashion using Wings for NONMEM (http:// wfn.sourceforge.net/). This procedure also provided statistics of the population parameters.
Visual predictive check (VPC) validation
Drug concentration profiles were simulated using the final population models and compared with the observed data to evaluate the predictive performance of the model. Prediction-corrected VPCs (pcVPCs) were used as informative diagnostic tools to allow inspection of model appropriateness across time as well as across covariate values. 21 Given the use of a mixture model, the predictions used for correction were weighted as previously described. 22 Fixed-dose combination of efavirenz/lamivudine/abacavir JAC Dose simulations-assessment of three different FDC strengths
For dose simulation, a dummy dataset was generated that included 1080 subjects with one observation each (1080 observations). The residual error variabilities, for each study, were included to account for intra-individual variability. Each subject's body weight was drawn from a uniform distribution between 10 and 35 kg. The proportion of slow metabolizers was fixed to 13%, closer to the expected proportion reported in sub-Saharan Africa. Monte Carlo simulations (87 and 13 replicates of this database for normal and slow metabolizers, respectively) were performed using the final model. The three FDCs described above (options I -III) were investigated. All possible dosages were considered assuming the use of a scored tablet that could be split in two.
For efavirenz the optimal targets were defined as: mid-dose interval (C 12 ) plasma concentration between 1 and 4 mg/L. 4 -6 For both lamivudine and abacavir the target was .75% of subjects with an AUC 0 -24 .8 mg . h/L. 14 Abacavir and lamivudine are well-tolerated drugs, and thus no toxicity target was assessed.
Results
Demographic data
A total of 505 patients and 3667 concentrations were available for the pharmacokinetic analysis. Table 1 summarizes the characteristics for the entire population that served for the development of the efavirenz model. Table S2 summarizes the details for each study.
Efavirenz population pharmacokinetics model
A two-compartment disposition model with first-order absorption and elimination could be identified. Thirty-three concentrations were below the LOQ, corresponding to ,1% of the total observations; these concentrations were set to half of the LOQ.
The addition of a transit absorption compartment (rate constant K TR ) significantly improved the fit. Addition of more than one transit compartment led to an increase in the OFV. The parameters of the model were the elimination and diffusional clearances (CL/F and Q/F), central and peripheral volumes of distribution (V c /F and V p /F), and the transit and absorption rate constants (K TR and K a ), with F being the relative bioavailability, whose typical value was fixed to 1. The BSV could be estimated for K a , CL/F and Vc/F. A BOV was estimated for F. The residual unexplained variability was ascribed to proportional and/or combined error models depending on the study.
After inclusion of the weight-based allometric scaling, age had no significant effect on clearance. Given the CYP2B-516G .T genotype status of subjects, the clearance distribution was ascribed to two or three subgroups [two or three CL subgroups, fast and/or normal and slow metabolizers (GG/GT and TT)]. Including these two genotype subgroups resulted in a 73 U drop in the OFV, and the BSV on CL/F decreased from 0.65 to 0.56. Although there was some trend for three CL subgroups, as indicated by drops in OFV, this was not retained for the final model since the addition of a third CL group did not result in a significant drop in the BSV of CL (from 0.56 to 0.55). Moreover, the proportions in each group were poorly estimated. Subjects with no genotype result, 37.2% of the total, were classified using a mixture model. 23 Table S3 summarizes the final population pharmacokinetic estimates. All the parameters were well estimated, given their relative standard error (RSE%) and bootstrap analysis.
Evaluation and validation of the efavirenz population pharmacokinetic model
The pcVPC plot shows that the median prediction matches the observed concentration -time curves and that the variability is reasonably estimated for efavirenz (see Figure S1 ). The 5th, 50th Figure 1 shows the proportion of patients with a predicted efavirenz C 12 within the 1 -4 mg/L therapeutic interval for option I (150/75/150 mg); the same procedure was repeated for FDC options II and III. For efavirenz: (i) the probability of being within the therapeutic range was between 56% and 60%, for all three FDCs; and (ii) for a given weight band, two or three dosages gave similar probabilities of achieving the therapeutic range. Within each weight band when the probabilities of being within the range were very similar, preference was given for the highest dose, thus minimizing the probability of therapeutic failure. For the three strength options, Figure 2 shows the percentage of children with an efavirenz C 12 below (risk of failure), within (acceptable) or above (risk of toxicity) the therapeutic range. Option I was found to provide a better and more uniform distribution across all weight bands. It also provided a good balance between failure and toxicity risks: with option I, underexposure (with C 12 ,1 mg/L) was always the smallest one (,15%) and overexposure (with C 12 .4 mg/L) was also the smallest one (maximum 32%), in contrast to the other options. Moreover, thanks to a mixed-effect logistic regression, options II and III provided higher probabilities of being overexposed (P,10 24 and P ¼ 0.023), showing that option I was the safer. For abacavir and lamivudine, simulations showed that for option I, as well as for options II and III (not shown), .75% of subjects were well above AUC efficacy targets, i.e. 8 mg . h/L for abacavir and lamivudine (Figures 2 and 3 ).
Discussion
Efavirenz pharmacokinetics was assessed in a large dataset of paediatric patients in order to establish an optimal paediatric FDC for efavirenz/lamivudine/abacavir. The broad spectrum of body weights within the large dataset allowed the investigation of the effect of growth on pharmacokinetic parameters. The efavirenz structural pharmacokinetic model, a two-compartment model in which the delay in absorption was described via one transit compartment, was consistent with a previous adult study. 24 Since all pharmacokinetic parameters do not change linearly with body mass, allometric scaling was introduced and greatly improved the model fit. No effect of age was observed after the inclusion of allometric scaling. This is possibly due to the fact that only a very small number of patients ,1 year of age were represented in the dataset and 90% of the agematuration effect is already achieved by 1.5 years for most drugs including efavirenz. 25 Efavirenz CL/F was significantly related to the CYP2B6-516G .T polymorphism, i.e. patients carrying the TT genotype had a more than 2-fold decreased CL relative Fixed-dose combination of efavirenz/lamivudine/abacavir JAC to the GG/GT genotype carriers. Including two clearance subgroups for efavirenz supported a recessive rather than additive genetic model, as previously reported also by the PACTG382 study. 26 When scaling the final estimates of CL to a standard 70 kg adult, the values of 6.1 and 15.6 L/h were obtained for the two CL groups, consistent with 11.7 L/h reported using a comparable model without metabolizer subgroups. 27 Using the final pharmacokinetic models, Monte Carlo simulations were performed to generate efavirenz C 12 values corresponding to the three proposed FDC strengths. Because pharmacokinetic parameters were allometrically scaled to body weight, the predicted C 12 values included both the body weight and dose information. This supported the validity of the statistics derived from the simulated C 12 values, i.e. the probability of each dose and each weight being within, above or under the therapeutic range.
Our study has some limitations. The simulations included only children weighing 10 -35 kg and .3 years of age, so our results should not be extrapolated beyond this population, especially to younger infants. Additionally, our analysis did not include information about CYP2B6-983T .C, which, although less prevalent than 516G .T, has been shown to have a stronger effect on reducing efavirenz clearance than 516G .T. 13 This second SNP can modify the metabolic subgroup allocation compared with the use of 516G .T only. However, this missing information is transferred into the unexplained random variability. This work is based on simulations from population modelling results in order to inform rational paediatric FDC design. These simulations should be prospectively confirmed with safety and efficacy studies.
The simulations show that an FDC of efavirenz/lamivudine/ abacavir of 150/75/150 mg is appropriate for children weighing 10 -35 kg. The relatively weak target attainment of 60% results from the narrow therapeutic range of efavirenz along with a wide between-subject variability. This could be partly overcome by genotyping and therapeutic drug monitoring. Children in the weight bands 10 -14, 14 -20, 20 -25, 25 -30 and 30 -35 kg, should receive respectively 1.5, 2, 2.5, 3 and 3.5 U of this solid dose formulation once daily. This formulation should be rapidly moved through for development as there is an urgent need for a once-daily paediatric FDC tablet.
Conclusions
Population pharmacokinetic modelling and simulations can be used to select the optimal proportions of each drug in an FDC. Accordingly, a paediatric fixed-dose efavirenz/lamivudine/abacavir formulation can achieve therapeutically effective and safe levels for all components across the WHO weight bands. This work also provides an example of how a pooled analysis of pharmacokinetic data from multiple studies can inform formulation development and offer an alternative approach to traditional pathways, contributing to faster development of priority FDCs.
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